Scientific program
| Thursday, 29 May 2025 | |
| 10:30-17:00 | Registration |
| 17:00-17:30 | Welcome coffee |
| 17:30-20:30 | Opening ceremony |
| Greeting of guests | |
| „For HAE Patients” Award | |
| Opening lecture Chairs: Anna Erdei, Bruce Zuraw |
|
| I-01 | Developing mRNA for therapy: My Journey Katalin Karikó |
| 20:30-22:00 | Welcome reception |
| Friday, 30 May 2025 | |
| 08:00-10:15 | Scientific Session I. Chairs: Alvin Schmaier, Tomaš Freiberger |
| 08:00-08:30 I-02 |
The protease inhibitor Inter-α-trypsin inhibitor heavy chain 4 (ITIH4) as a compensatory inhibitor in plasma of hereditary angioedema patients Steffen Thiel |
| 08:30-08:45 O-01 |
Non-peptide bradykinin B2 receptor ligands possessing a quinolinyl moiety, or variants thereof: pharmacological properties and computational prediction of binding modes François Marceau |
| 08:45-09:00 O-02 |
Clinical validation of a novel biomarker assay to characterise bradykinin-mediated angioedema in prospective and biobank plasma samples Evangelia Pardali |
| 09:00-09:15 O-03 |
Impact of C1-inhibitor binding to endothelial cells on the regulation of vascular permeability Sonia Caccia |
| 09:15-09:30 O-04 |
Systemic inflammation biomarkers in different endotypes of angioedema Johana Gil Serrano |
| 09:30-09:45 O-05 |
Identification of candidate biomarkers for diagnosing and assessing the disease severity of type 2 hereditary angioedema via plasma N-glycomics Yingyang Xu |
| 09:45-10:00 O-06 |
Inhibition of Bradykinin Liberation by plasma Kallikrein inhibitors ameliorates vasogenic edema in experimental (Murine) cerebral malaria independent of and in addition to artesunate Alvin Schmaier |
| 10:00-10:15 O-07 |
Differentiating subtypes of angioedema with machine learning Toan Do |
| 10:15-10:45 | Coffee break |
| 10:45-13:00 | Scientific Session II. Chairs: Anastasios Germenis, Matija Rijavec |
| 10:45-11:15 I-03 |
Incidental findings related to genes associated to HAE-nC1INH: How to proceed? Anastasios Germenis |
| 11:15-11:30 O-08 |
Clinical and genetic characterization of three families with homozygous SERPING1 mutations in hereditary angioedema Asuman Çamyar |
| 11:30-11:45 O-09 |
What can we learn from genome sequencing in HAE C1inh-nl? Julie Gauthier |
| 11:45-12:00 O-10 |
Preliminary demographic and clinical data from a cohort of Spanish HAE-C1INH patients: The GenomAEH Study Mar Guilarte |
| 12:00-12:15 O-11 |
Genetic double strike in C1INH deficiency Hereditary Angioedema: when rare become ultra rare - Patient case series from a monocentric Italian cohort Paola Triggianese |
| 12:15-12:30 O-12 |
Cosegregation study of kallikrein-kinin system genes in a cohort of 8 unrelated families with HAE-C1INH in Southern Spain Krasimira Baynova |
| 12:30-12:45 O-13 |
Identification of a novel XPNPEP2 variant associated with hereditary angioedema with normal C1-INH activity - A molecular insight Sandra Nieto |
| 12:45-14:15 | Lunch break |
| 14:15-15:45 | Pediatric HAE Guideline |
| 15:45-17:30 | Poster Session I. P01-P29 with Coffee break Chairs: Sladjana Andrejevic, Mauro Cancian, Danny Cohn, Timothy Craig |
| P-01 | Hereditary angioedema with normal C1Inh and PLG mutation treated with tranexamic acid : Beware of the risk of thrombosis Bocquet Alexis |
| P-02 | Challenges of Diagnosis and treatment of recurrent angioedema from Nepal - The unseen struggle in resource-constrained settings Dharmagat Bhattarai |
| P-03 | Why are some HAE patients more resistant to prophylaxis than others? Shira Benor |
| P-04 | Hereditary angioedema due to factor XII mutation: clinical manifestations among males subjects Delphine Gobert |
| P-05 | Acquired angioedema: A case of recurrent angioedema for two years after a successful treatment and normalization of the C1 inhibitor level Sladjana Andrejevic |
| P-06 | The effect of surgical and interventional procedures on attack frequency in hereditary angioedema patients Ecem Ay |
| P-07 | Investigating the risks of long-term glucocorticoid and attenuated androgen use in patients with angioedema: A systematic literature review Thomas Buttgereit |
| P-08 | Unmet needs and systemic challenges of HAE pediatric patient families in Europe Camelia Isaic |
| P-09 | Exploring the Impact of Psychological Burden in Hereditary Angioedema with the Pictorial Representation of Illness and Self Measure (PRISM) Tool Delphine Gobert |
| P-10 | Lanadelumab leads to meaningful quality of life improvement and reduced productivity loss in patients with HAE: final results from the ENABLE Study Emel Aygören-Pürsün |
| P-11 | Infection rates in patients with Hereditary Angioedema treated with garadacimab Mauro Cancian |
| P-12 | NTLA-2002 mechanism of action, pharmacology, safety, and efficacy in hereditary angioedema Danny M Cohn |
| P-13 | THERAPEUTIC TRENDS IN LONG-TERM PROPHYLAXIS IN ADULT HAE PATIENTS IN SERBIA 2020-2024 Radovan Mijanovic |
| P-14 | Garadacimab-mediated inhibition of activated factor XII does not increase risk of thrombosis in patients with HAE Emel Aygören-Pürsün |
| P-15 | Rationale and design of the Garadacimab REAl-world Treatment outcomes of effectiveness, safety and quality-of-life in patients with hereditary angioedema (GREAT) study Andrea Zanichelli |
| P-16 | Avoiding Misdiagnosis in Hereditary Angioedema: A Case Report Irina Guryanova |
| P-17 | Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures Andrea Zanichelli |
| P-18 | In Their Own Words, Patient Perspectives on Time to Feeling in Control of an HAE Attack Douglas Jones |
| P-19 | Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study Markus Magerl |
| P-20 | Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers Zhi-Yi Zhang |
| P-21 | Optical genome mapping for the identification of complex structural variants in hereditary angioedema due to C1-inhibitor deficiency Roger Colobran |
| P-22 | Somatic variants and mosaicism in hereditary angioedema due to C1-inhibitor deficiency: implications for genetic counselling Roger Colobran |
| P-23 | First Bulgarian Family with Hereditary Angioedema Due to Plasminogen Gene Mutation: Clinical Insights and Treatment Approaches Alex Fam |
| P-24 | Bradykinin Dilemma: Angioedema or Mere Mimicry Ferhat Maksudov |
| P-25 | Time to end of progression of hereditary angioedema attacks treated with sebetralstat William R. Lumry |
| P-26 | Clinical investigation of hereditary angioedema linked to coagulation factor XII mutations in a southern Spanish cohort Teresa De Aramburu Mera |
| P-27 | Genetic segregation study in patients with hereditary angioedema due to mutation in coagulation factor XII in a population of southern Spain. Teresa De Aramburu Mera |
| P-28 | Quality of Life in elderly patients affected by Hereditary Angioedema: data from the ITACA Register Francesca Perego |
| P-29 | Impact of injectable HAE on-demand treatments on health-related quality of life: a patient and caregiver interview study Patrick Yong |
| Saturday, 31 May 2025 | |
| 08:00-10:00 | Scientific Session III. Chairs: Teresa Caballero, William Lumry |
| 08:00-08:15 O-14 |
Preliminary results from Epidemiological survey of hereditary angioedema in India- just a tip of the iceberg Ankur Kumal Jindal |
| 08:15-08:30 O-15 |
HAE with normal C1Inh (HAE-n C1INH) and spontaneous mast cell AE (AE-MC): Clinical similarities and differences Alexis Bocquet |
| 08:30-08:45 O-16 |
Complement characteristics in angioedema due to acquired C1-inhibitor deficiency: A clinico-biological correlation Leo Guennoun |
| 08:45-09:00 O-18 |
Hereditary angioedema: A national investigation of associated comorbidities and surgical procedures Lili Voloncs-Mindszenthy |
| 09:00-09:15 O-19 |
Clinical expressions, disease course, quality-of-life and resilience in subgroups of patients with angioedema Iris Leibovich-Nassi |
| 09:15-09:30 O-20 |
Triggers in focus: A deep dive into what sets off HAE attacks Adil Bahadir |
| 09:30-09:45 O-21 |
Angiotensin converting enzyme inhibitor angioedema in an African population, a case control cohort Cascia Day |
| 09:45-10:00 O-22 |
Psychometric study of specific questionnaires HAE-QoL and AE-QoL and the generic questionnaire EQ-5D-5L in adult patients with hereditary angioedema due to C1 inhibitor deficiency Teresa Caballero |
| 10:00-10:30 | Coffee break |
| 10:30-12:30 | Scientific Session IV. Chairs: Markus Magerl, Marc Riedl |
| 10:30-11:00 I-04 |
Body vs. Antibody – Behavior of monoclonal therapeutic antibodies in Angioedemas László Cervenak |
| 11:00-11:15 O-23 |
Long-term efficacy and safety of prophylactic treatment with once-daily deucrictibant for angioedema due to acquired C1-inhibitor deficiency: final study results Mats de Lange |
| 11:15-11:30 O-24 |
Garadacimab-mediated inhibition of activated factor XII had no impact on haemostasis in patients with hereditary angioedema Timothy J. Craig |
| 11:30-11:45 O-25 |
Lanadelumab shows infrequent injection site reactions and high patient satisfaction in patients with HAE: ENABLE Study Results Mauro Cancian |
| 11:45-12:00 O-26 |
Reduction in percentage of days with angioedema symptoms among young children initiating berotralstat: Interim results from APeX-P Tamar Kinaciyan |
| 12:00-12:15 O-27 |
Lanadelumab’s enduring impact on HAE attack reduction and improved disease control: final results from the ENABLE Study Andrea Zanichelli |
| 12:15-12:30 O-28 |
Normalization of elevated D-dimer with donidalorsen treatment across phase 2 and phase 3 studies in patients with hereditary angioedema Andrea Zanichelli |
| 12:30-14:00 | Lunch break |
| 14:00-16:15 | Scientific Session V. Chairs: Anete S. Grumach, Connie Katelaris |
| 14:00-14:30 I-05 |
Assessment of risk and benefit in clinical trials: Challenges in rare diseases Bruce Zuraw |
| 14:30-14:45 O-29 |
Effectiveness of sebetralstat for the on-demand treatment of mucosal hereditary angioedema attacks: interim analysis from KONFIDENT-S Henriette Farkas |
| 14:45-15:00 O-30 |
Navenibart for Hereditary Angioedema (HAE): analysis of safety, pharmacokinetic, and pharmacodynamic data from Phase 1a and Phase 1b/2 ALPHA-STAR trial Marc A. Riedl |
| 15:00-15:15 O-31 |
HAELO, a phase 3, global, randomised, double-blind, placebo-controlled study of NTLA-2002, a CRISPR-based gene editing therapy, in participants with hereditary angioedema Emel Aygören-Pürsün |
| 15:15-15:30 O-32 |
Anxiety associated with hereditary angioedema attacks: results from the phase 3 KONFIDENT trial of oral sebetralstat Timothy J. Craig |
| 15:30-15:45 O-33 |
Long-term safety and efficacy of oral deucrictibant for prophylaxis in hereditary angioedema: data snapshot results of the chapter-1 open-label extension study Emel Aygören-Pürsün |
| 15:45-16:00 O-34 |
Long-term safety and efficacy of oral deucrictibant for treatment of hereditary angioedema attacks: Results of the rapide-2 extension study Marc A. Riedl |
| 16:00-16:15 O-35 |
ADX-324, a Q6-month SC investigational siRNA targeting Prekallikrein for HAE attack prevention Robert MacLeod |
| 16:15-17:45 | Poster Session II. P30-P58 with Coffee break Chairs: Sandra Christiansen, Stefan Cimbollek, Milos Jesenak, Hilary Longhurst |
| P-30 | Epidemiology of Bradykinin-Mediated Angioedema in the European Population Emel Aygören-Pürsün |
| P-31 | Assessing the diagnostic value of complement testing in Type I Hereditary Angioedema in a pediatric population Monica Colque-Bayona |
| P-32 | Survey results from Italy, the US, UK, and France: Anxiety in patients using injectable on-demand treatments for hereditary angioedema attacks Mauro Cancian |
| P-33 | Limited access to On-Demand Treatment for Hereditary Angioedema has an impact on Quality of life: a comparison between two income settings Cascia Day |
| P-34 | Physician and Patient level of agreement in hereditary angioedema attack reporting among a real-world European population Mauro Cancian |
| P-35 | Physician-reported outcomes versus location of attack in a real-world hereditary angioedema patient population in Europe Laurence Bouillet |
| P-36 | Distinct SERPING1 Variants and Genetic Modifiers Influencing Disease Expression in Hereditary Angioedema due to C1-Inhibitor Deficiency Matija Rijavec |
| P-37 | Bioequivalence of lanadelumab 300 mg subcutaneous injection administered via the pre-filled syringe and pre-filled pen Irmgard Andresen |
| P-38 | Impact of sex on the course of hereditary angioedema due to C1 inhibitor deficiency Hanga Réka Horváth |
| P-39 | Candidate variants associated with Hereditary Angioedema with normal C1-Inhibitor Helena Jakopič |
| P-40 | Effect of COVID-19 Infection on Hereditary Angioedema (HAE) – Survey of Canadian Patients Amarjot Kang |
| P-41 | Increased risk of systemic lupus erythematosus in individuals with hereditary angioedema: a family study Linda Sundler Björkman |
| P-42 | CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks Andrea Zanichelli |
| P-43 | Genetic features of bradykinin-forming cascade and vascular endothelium permeability regulation pathways in Brazilian families with recurrent angioedema Clarissa A. Bittencourt |
| P-44 | Utility of Abdominal Ultrasound in the Diagnosis of Abdominal Angioedema Fiorella Adrianzen |
| P-45 | Phenotype and SERPING1 genotype of a cohort of 46 unrelated families with HAE-C1INH from Southern Spain Krasimira Baynova |
| P-46 | Genetic insights in pediatric Hereditary Angioedema: Two cases treated with lanadelumab Laurel-Laurel Rolando |
| P-47 | An update on SERPING1 variants identified in Hungarian patients with hereditary angioedema, including patients with two alterations and novel variants Ágnes Szilágyi |
| P-48 | Atypical Presentation of Hereditary Angioedema- A Case of HS3ST6 Mutation with Uncommon Symptoms and Normal C1-INH Levels Sandra Nieto |
| P-49 | First comprehensive report of hereditary angioedema due to C1 inhibitor deficiency in Bosnia and Herzegovina: one novel mutation and genotype-phenotype association Mensuda Hasanhodzic |
| P-50 | Hereditary Angioedema Breakthrough: FXII Mutation Discovery and the Power of Icatibant and Lanadelumab Eyal Ben Dori |
| P-51 | Development of a WB-based method to quantify different forms of C1INH in HAE-C1INH-Type2, based on the example of the R444C variant Bence Farkas |
| P-52 | Uncovering Urinary Protein Biomarkers for Early Diagnosis and Evaluation of Hereditary Angioedema Yuxiang Zhi |
| P-53 | Proactive identification of rare diseases: Lessons from hereditary angioedema diagnosis using electronic medical records Xue Wang |
| P-54 | Factors Influencing Quality of Life in Angioedema Due to C1-Inhibitor Deficiency: A Single-Center Experience Riccardo Senter |
| P-55 | Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study Ramon Lleonart Bellfill |
| P-56 | Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacks Anna Valerieva |
| P-57 | DEFICIT-syndrome, a novel entity in cerebral vasogenic oedema Simon Péter Nagy |
| P-58 | Hereditary Angioedema (HAE) and Post Traumatic Stress Disorder (PTSD) Sandra Christiansen |
| Sunday, 1 June 2025 | |
| 08:00-09:30 | Scientific Session VI. Chairs: Ankur Jindal, Laurence Bouillet |
| 08:00-08:15 O-36 |
Transient hepatitis after discontinuation of danazol in patients with hereditary angioedema due to C1-inhibitor deficiency: a case series Danny Cohn |
| 08:15-08:30 O-37 |
Very long-term efficacy of oral Berotralstat-LTP in hereditary angioedema patients Tamar Kinaciyan |
| 08:30-08:45 O-38 |
Tolerability and effectiveness of Berotralstat for Prophylaxis in adolescents with hereditary angioedema: Subgroup analysis of the berolife study Isabelle Boccon-Gibod |
| 08:45-09:00 O-39 |
Long-term prophylaxis usage for hereditary angioedema by Canadian physicians Natasha Correa |
| 09:00-09:15 O-40 |
Berotralstat for the prevention of hereditary angioedema attacks: Results from the Italian expanded access programme Riccardo Senter |
| 09:15-09:30 O-41 |
Real-world effectiveness of lanadelumab in hereditary angioedema in Slovakia – a 4-year experience Milos Jesenak |
| 09:30-10:00 | Coffee break |
| 10:00-11:30 | Scientific Session VII. Chairs: Paul Keith, Tamar Kinaciyan |
| 10:00-10:15 O-42 |
Harnessing innovation to collect data for Harpe, a dynamic French registry of patients with hereditary angioedema: results from the single-centre phase Alexis Bocquet |
| 10:15-10:30 O-43 |
Turkish National hereditary angioedema and acquired angioedema registry, HAE/AAE-TR Nihal Mete Gökmen |
| 10:30-10:40 O-44 |
Case report: A 5-year-old boy with a truncating ANGPT1 mutation, possibly associated with hereditary angioedema with normal C1 inhibitor Christina Weber-Chrysochoou |
| 10:40-10:50 O-45 |
Clinical evidence for a cross-talk between mast-cells and bradykinin-mediated angioedema: Case report and discussion Avner Reshef |
| 10:50-11:00 O-46 |
Ureteral edema and hydronephrosis associated with hereditary angioedema attack Züleyha Galata |
| 11:00-11:10 O-47 |
The reduction of hereditary angioedema attacks following significant weight loss achieved through bariatric surgery Marko Barešić |
| 11:10-11:20 O-48 |
Hereditary angioedema and autoimmune thyroiditis in a preadolescent female Gabriel E. Arce-Estrada |
| 11:20-11:30 O-49 |
Is angioedema a clinical manifestation of immunodeficiency? Angioedema in heterozygous mutation of the PIK3R1 gene Vania María Miranda Saavedra |
| 11:30-12:15 | Closing Remarks |
| 12:15-14:00 | Lunch |
| 14:00- | Departure |
